Chang et al. identified that oncogenic KRAS upregulated survivin expression by activating extracellular-signal-regulated kinase 1/2 (ERK1/2) in pancreatic cancer cells, which in turn protected MYC from degradation to promote malignant transformation [40]. The gene discussed is MAPK3; the disease is pancreatic neoplasm.